Cerus Stock Forecast, Price & News

Cerus' stock was trading at $4.76 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CERS shares have increased by 27.7% and is now trading at $6.08.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cerus.

Cerus is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cerus.

Cerus Co. (NASDAQ:CERS) issued its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The biotechnology company had revenue of $21.50 million for the quarter, compared to the consensus estimate of $21.50 million. Cerus had a negative net margin of 83.78% and a negative return on equity of 76.83%.
View Cerus' earnings history.

Cerus issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $112.8 million.

4 brokerages have issued 12-month target prices for Cerus' shares. Their forecasts range from $6.50 to $9.00. On average, they expect Cerus' stock price to reach $7.63 in the next year. This suggests a possible upside of 25.4% from the stock's current price.
View analysts' price targets for Cerus.

Cerus saw a increase in short interest in August. As of August 31st, there was short interest totaling 11,430,000 shares, an increase of 15.2% from the August 15th total of 9,920,000 shares. Based on an average trading volume of 1,900,000 shares, the days-to-cover ratio is presently 6.0 days.
View Cerus' Short Interest.

Some companies that are related to Cerus include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), OraSure Technologies (OSUR), Meridian Bioscience (VIVO), Anika Therapeutics (ANIK) and Antares Pharma (ATRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Opko Health (OPK), Pfizer (PFE), Immunomedics (IMMU), ACADIA Pharmaceuticals (ACAD), Novavax (NVAX) and Advanced Micro Devices (AMD).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus' stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.54%), Vanguard Group Inc. (5.31%), Paradigm Capital Management Inc. NY (0.92%), Peregrine Capital Management LLC (0.88%), Nuveen Asset Management LLC (0.81%) and Intrinsic Edge Capital Management LLC (0.72%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman.
View institutional ownership trends for Cerus.

CERS stock was sold by a variety of institutional investors in the last quarter, including Pier Capital LLC, Intrinsic Edge Capital Management LLC, Silvercrest Asset Management Group LLC, Peregrine Capital Management LLC, FMR LLC, FMR LLC, Paradigm Capital Management Inc. NY, and Lesa Sroufe & Co. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

CERS stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., UBS Group AG, Marshall Wace North America L.P., EAM Investors LLC, Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Nuveen Asset Management LLC, and Cubist Systematic Strategies LLC. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $6.08.

Cerus has a market capitalization of $1.01 billion and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.

The official website for Cerus is www.cerus.com.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]